XML 131 R108.htm IDEA: XBRL DOCUMENT v3.25.0.1
(Schedules of Concentration of Risk) (Details)
1 Months Ended 6 Months Ended 11 Months Ended 12 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Jun. 16, 2022
Nov. 14, 2023
Dec. 27, 2024
Dec. 29, 2023
Distributor Concentration Risk | Revenue from Contract with Customer Benchmark [Member] | CuraScript, Inc [Member]            
Concentration Risk [Line Items]            
Concentration risk, percentage     15.60%      
Distributor Concentration Risk | Revenue from Contract with Customer Benchmark [Member] | McKesson Corporation [Member]            
Concentration Risk [Line Items]            
Concentration risk, percentage 10.80%          
Distributor Concentration Risk | Revenue from Contract with Customer Benchmark [Member] | Amerisource Bergen Corporation [Member]            
Concentration Risk [Line Items]            
Concentration risk, percentage       10.00% 13.80%  
Distributor Concentration Risk | Revenue from Contract with Customer Benchmark [Member] | FFF Enterprises, Inc.            
Concentration Risk [Line Items]            
Concentration risk, percentage 23.10% 26.10% 11.80% 22.30% 23.10%  
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | McKesson Corporation [Member]            
Concentration Risk [Line Items]            
Concentration risk, percentage         19.80% 20.00%
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | Amerisource Bergen Corporation [Member]            
Concentration Risk [Line Items]            
Concentration risk, percentage         34.90% 24.20%
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | FFF Enterprises, Inc.            
Concentration Risk [Line Items]            
Concentration risk, percentage         12.10%  
Product Concentration Risk | Net Sales Attributable to Products | Acthar Gel            
Concentration Risk [Line Items]            
Concentration risk, percentage 23.50% 28.30% 25.40% 22.70% 24.50%  
Product Concentration Risk | Net Sales Attributable to Products | Inomax            
Concentration Risk [Line Items]            
Concentration risk, percentage 14.50% 16.70% 19.00% 16.50% 13.20%  
Product Concentration Risk | Net Sales Attributable to Products | Therakos            
Concentration Risk [Line Items]            
Concentration risk, percentage 16.10% 12.50% 12.50% 13.60% 12.20%  
Product Concentration Risk | Net Sales Attributable to Products | APAP            
Concentration Risk [Line Items]            
Concentration risk, percentage 13.40% 10.70% 11.00% 11.40%